Cost and Resource Utilization Associated With Fluconazole as First-Line Therapy for Invasive Candidiasis: A Retrospective Database Analysis

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2467-2477

  Craver, Christopher W ^a   Tarallo, Miriam ^b   Roberts, Craig S ^b   Blanchette, Christopher M ^c,d   Ernst, Frank R ^a  

^a Premier Inc   (United States)

^b PFIZER INC   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Candidemia; Candidiasis; Cost; Fluconazole; Health economics; Resource use

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ARTICLE; CANDIDIASIS; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; RESOURCE UTILIZATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; FLUCONAZOLE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79951831158     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.001     Document Type: Article

References (22)

1. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317. [published correction appears in Clin Infect Dis. 2004;39:1093, Clin Infect Dis. 2005;40:1077].
3. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008, 29:978-980.
4. Horn D.L., Neofytos D., Anaissie E.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
5. Chang A., Neofytos D., Horn D. Candidemia in the 21st century. Future Microbiol 2008, 3:463-472.
6. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
7. Wilson L.S., Reyes C.M., Stolpman M., Speckman J., Allen K., Beny J. The direct cost and incidence of systemic fungal infections. Value Health 2002, 5:26-34.
8. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
9. Rentz A.M., Halpern M.T., Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27:781-788.
10. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630. National Nosocomial Infections Surveillance System Hospitals.
11. Pfaller M.A., Diekema D.J., Rinaldi M.G., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: A 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005, 43:5848-5859.
12. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991, 325:1274-1277.
13. Kett D.H., Cubillos G.F. Anidulafungin in the treatment of patients with invasive candidiasis. Int J Antimicrob Agents 2008, 32(Suppl 2):S99-S102.
14. Averill R., Goldfield N., Hughes J., et al. What are APR-DRGs?. An introduction to severity of illness and risk of mortality adjustment methodology 3M Health Information Systems, 2003, Accessed December 7, 2010. http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?locale=it_IT%26univid=1180603360910%26fallback=true%26assetType=MMM_Image%26blobAttribute=ImageFile%26placeId=7BC6E48B1800BAE180A88E4927002AEF%26version=current.
15. Gagne J.J., Goldfarb N.I. Candidemia in the in-patient setting: Treatment options and economics. Expert Opin Pharmacother 2007, 8:1643-1650.
16. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. Infectious Diseases Society of America.
17. Gagne J.J., Breitbart R.E., Maio V., et al. Costs associated with candidemia in a hospital setting. Pharm Ther 2006, 31:586-619.
18. Schonfeld W., Wang Cheng J., Tong K.B., Seifeldin R. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther 2008, 30:964-973.
19. Edelsberg J., Berger A., Weber D.J., Mallick R., Kuznik A., Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008, 29:160-169.
20. Edelsberg J., Berger A., Schell S., et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008, 9:335-347.
21. Reboli A.C., Rotstein C., Pappas P., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2782. Anidulafungin Study Group.
22. Hajjeh R.A., Sofair A.N., Harrison L.H., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519-1527.